Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2025-04-28 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力2025年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2025 First Quarter Report" of 天士力医药集团股份有限公司, indicating it is a quarterly financial report. It contains detailed financial statements including balance sheets, profit and loss statements, cash flow statements, and notes on financial data for the first quarter of 2025. The report explicitly states it is unaudited and covers the period January to March 2025. The presence of comprehensive financial data and analysis for a period shorter than a full fiscal year confirms it is an Interim / Quarterly Report. It is not an announcement or a brief summary but a full report with substantive financial content. Q1 2025
2025-04-28 Chinese
天士力关于公司2025年第一季度主要经营数据的公告
Interim / Quarterly Report Classification · 90% confidence The document is titled as an announcement regarding the company's main operating data for the first quarter of 2025. It contains detailed financial data such as revenue, cost, and gross margin segmented by industry, treatment field, product, and region for the quarter. The document explicitly states it is a disclosure of main operating data for the quarter and is unaudited. It does not contain full financial statements or comprehensive analysis typical of an Interim/Quarterly Report (IR), but rather a summary of key operating metrics for the quarter. The document length is 2813 characters, which is relatively short but contains substantive financial data rather than just an announcement of a report. Therefore, it fits best as an Interim / Quarterly Report (IR) because it provides substantive financial data for a period shorter than a full fiscal year (the first quarter). Q1 2025
2025-04-28 Chinese
天士力关于公司2025年度担保预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from TianShiLi Pharmaceutical Group Co., Ltd. regarding the company's expected guarantees for the year 2025. It details the guarantee amounts, the companies being guaranteed (subsidiaries and sub-subsidiaries), financial data of these entities, internal decision procedures, and board opinions. The document is structured as a formal announcement about the company's planned guarantee commitments for the upcoming fiscal year. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or interim reports. It is not a report itself but an announcement about expected guarantees and related corporate actions. Therefore, it fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2025-04-28 Chinese
天士力2025年第二次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as "2025 年第二次临时股东大会会议资料" which translates to "2025 Second Extraordinary General Meeting (EGM) Meeting Materials." It contains detailed agenda, voting procedures, attendance information, and a specific proposal regarding the increase of expected daily related-party transactions for 2025. The document includes voting methods, legal opinion, and signatures related to the shareholder meeting. It is not a full financial report, audit report, or earnings release. It is not a proxy solicitation or voting results announcement but rather the materials provided for the shareholders to review before or during the meeting. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting. The document length (9021 characters) and content confirm it is the meeting materials themselves, not just an announcement of a report publication or voting results. Therefore, the correct classification is AGM Information (AGM-R).
2025-04-25 Chinese
天士力于增加2025年预计发生的日常关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the increase in expected daily related-party transactions for the year 2025 by TianShiLi Pharmaceutical Group Co., Ltd. It details the nature of these transactions, the related parties involved, the approval process by the board and shareholders, and the pricing policies. The document is a formal disclosure about related-party transactions and their expected amounts, not a financial report or audit. It is not an annual or interim report, earnings release, or management discussion. It is also not a proxy statement or voting result announcement. The document is a regulatory announcement about related-party transactions, which fits best under the category of Regulatory Filings (RNS) as it is a compliance disclosure required by stock exchange rules and does not constitute a full report or financial statement.
2025-04-15 Chinese
天士力关于召开2025年第二次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about convening the 2025 second extraordinary general meeting of shareholders for TianShiLi Pharmaceutical Group Co., Ltd. It includes details about the meeting date, voting methods, agenda items, and instructions for shareholders. There is no financial data, earnings, or report content. It is an announcement related to a shareholder meeting, not the meeting materials or results themselves. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings. The document is detailed and specific to the meeting notice, so confidence is high.
2025-04-15 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.